Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis

BACKGROUND: Untreated hemophilia A patients may experience recurrent bleeding events leading to debilitating joint damages. While RCT and pharmacokinetic data support the value of Kovaltry [an unmodified full-length recombinant factor VIII (FVIII) product], real world evidence in children is lacking...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Hara, Jamie, Hirst, Ceri, Cabre Marquez, Jose Francisco, Burke, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809751/
https://www.ncbi.nlm.nih.gov/pubmed/33451335
http://dx.doi.org/10.1186/s13023-021-01676-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809751/
https://www.ncbi.nlm.nih.gov/pubmed/33451335
http://dx.doi.org/10.1186/s13023-021-01676-w

Ejemplares similares